Contribution of spinal μ1-opioid receptors and dynorphin B to the antinociception induced by Tyr-d-Arg-Phe-Sar

  title={Contribution of spinal $\mu$1-opioid receptors and dynorphin B to the antinociception induced by Tyr-d-Arg-Phe-Sar},
  author={H. Mizoguchi and Kanenori Ito and Hiroyuki Watanabe and C. Watanabe and S. Katsuyama and T. Fujimura and T. Sakurada and S. Sakurada},
The antinociceptive effect of Tyr-d-Arg-Phe-Sar (TAPS) at the spinal level was characterized with the mouse tail-flick test. Intrathecal (i.t.) administration of TAPS produced a dose-dependent antinociception. The antinociception induced by TAPS was completely blocked by i.t. pretreatment with the mu-opioid receptor antagonist beta-funaltrexamine, the mu(1)-opioid receptor antagonist naloxonazine or the kappa-opioid receptor antagonist nor-binaltorphimine, but not with the delta-opioid receptor… Expand
Involvement of spinal release of α-neo-endorphin on the antinociceptive effect of TAPA
The results suggest that the spinal antinociception induced by TAPA is mediated in part through the release of α-neo-endorphin in the spinal cord via activation of spinal μ1-opioid receptors. Expand
Involvement of mouse μ-opioid receptor splice variants in the spinal antinociception induced by the dermorphin tetrapeptide analog amidino-TAPA.
The present results suggest that the spinal antinociception of Amidino-TAPA is partially mediated through the activation of the amidino- TAPA-sensitive and DAMGO-insensitive mMOR-1 splice variants, which contain the sequence encoded by exon-12, ex-on-13 and ex-14, respectively. Expand
Distinct physiological role of amidino-TAPA-sensitive and DAMGO-insensitive μ-opioid receptor splice variants in the mouse spinal cord.
The physiological role of the distinct splice variants for cloned mouse μ-opioid receptor (mMOR-1), mMOR-1J, mMOR-1K and mMOR-1L, which are sensitive to N(α)-amidino-Tyr-D-Arg-Phe-β-AlaExpand
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
Data obtained by tail flick test showed that LP1 induced predominantly MOR-mediated supraspinal antinociception and was able to counteract DPDPE analgesia, a selective DOR agonist. Expand
Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine
The dermorphin N-terminal tetrapeptide analogs containing d-Arg(2) may provide a new target molecule for developing novel analgesics that have fewer side effects and are resistant to enzymatic metabolism. Expand
New vistas in opioid control of pain.
The μ-opioid receptors mainly contribute to the control of pain transmission, while a number of splice variants may have different physiological roles. In fact, some μ-opioid receptor agonists showExpand
Exploring µ-Opioid Receptor Splice Variants as Specific Molecular Target for New Analgesics.
The splice variants, sensitive to these new analgesics but insensitive to morphine, may be a better molecular target to develop the analgesics without side effects. Expand
The role of protein convertases in bigdynorphin and dynorphin A metabolic pathway
Dynorphins are important neuropeptides with a central role in nociception and pain alleviation. Many mechanisms regulate endogenous dynorphin concentrations, including proteolysis. ProproteinExpand
Endogenous opiates and behavior: 2006
This paper is the 29th consecutive installment of the annual review of research concerning the endogenous opioid system, and summarizes papers published during 2006 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. Expand
Design and Synthesis of Conformationally Constrained Compounds as New Tramadol- like Candidates
The author reveals how different pharmacological interventions through distinct analgesic mechanisms of action approaches multiple mechanisms of pain signaling and modulation in the context of multidrug analgesic combination therapy and multitarget approach. Expand


Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors.
Results indicate that TAPA can act as a highly selective mu(1)-opioid receptor agonist (notable naloxonazine-sensitive receptor agonists) at not only the supraspinal level, but also the spinal level, and reveal different antinociceptive mechanisms for DAMGO and for T APA. Expand
Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone
The present results suggest that endomorphin-1 and endomorphicin-2 may produce antinociception through different subtypes of mu-opioid receptor through different types of receptors in spinal sites. Expand
Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception.
The results indicate that endomorphins may produce antinociception through the distinct mu1 and mu2 subtypes of mu-opioid receptor. Expand
Differential antinociception induced by spinally administered endomorphin-1 and endomorphin-2 in the mouse.
It is proposed that there are at least two different subtypes of micro-opioid receptors for endomorphin-1 and endomorphicin-2 to produce antinociception in the spinal cord. Expand
Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
The data suggest that CP55,940 induces a release of spinal dynorphin B that contributes at least in part to its antinociceptive effects in the spinal cord. Expand
Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide 1 Published on the World Wide Web on 18 January 2000. 1
Comparing dynorphin B released from perfused rat spinal cord in response to acute administration of anandamide, Delta(9)-THC and CP55,940 at two time points, 10 min and 30 min post administration, confirms that although all three test drugs produced significant antinociception at 10 min, the endocannabinoid, AEA, does not induce antinOCiception via dynorphIn release. Expand
Dermorphin analog Tyr-D-Arg2-Phe-sarcosine-induced opioid analgesia and respiratory stimulation: the role of mu 1-receptors?
The antinociceptive, cataleptic and respiratory stimulant effects of TAPS appear to be a related to its agonist action at the mu 1 opioid receptors. Expand
Contribution of spinal mu1-opioid receptors to morphine-induced antinociception.
The present results suggest that the antinociceptive activity of both i.t. and i.c.v. morphine on responses to chemical and thermal stimuli may be mediated through the mu1-opioid receptor subtype (naloxonazine-sensitive sites). Expand
Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse.
The results indicate that endomorphin-2 given i.t.) produces its antinociceptive effects via the stimulation of mu (1)-opioid receptors (naloxonazine-sensitive site) in the spinal cord through the stimulated release of dynorphin A and [Met(5)]enkephalin. Expand
Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice.
The findings suggest that DAGO produces analgesia spinally and supraspinal through different sets of mu-receptors, and that the delta-antagonist ICI-154,129 is a more potent inhibitor of spinal DPDPE analgesia than spinal D AGO analgesia. Expand